Principal Financial Group Inc. Has $134,000 Stock Position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)

Principal Financial Group Inc. cut its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 95.7% during the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm owned 17,807 shares of the biotechnology company's stock after selling 393,607 shares during the period. Principal Financial Group Inc.'s holdings in BioCryst Pharmaceuticals were worth $134,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Counterweight Ventures LLC raised its holdings in BioCryst Pharmaceuticals by 591.7% during the 3rd quarter. Counterweight Ventures LLC now owns 93,384 shares of the biotechnology company's stock worth $710,000 after buying an additional 79,884 shares during the period. The Manufacturers Life Insurance Company raised its holdings in shares of BioCryst Pharmaceuticals by 40.7% during the third quarter. The Manufacturers Life Insurance Company now owns 299,152 shares of the biotechnology company's stock valued at $2,274,000 after acquiring an additional 86,571 shares during the period. Fisher Asset Management LLC lifted its position in shares of BioCryst Pharmaceuticals by 16.9% in the 3rd quarter. Fisher Asset Management LLC now owns 3,338,062 shares of the biotechnology company's stock valued at $25,369,000 after acquiring an additional 481,359 shares in the last quarter. Charles Schwab Investment Management Inc. boosted its stake in BioCryst Pharmaceuticals by 5.8% in the 3rd quarter. Charles Schwab Investment Management Inc. now owns 1,887,994 shares of the biotechnology company's stock worth $14,349,000 after purchasing an additional 102,860 shares during the period. Finally, Geode Capital Management LLC grew its position in BioCryst Pharmaceuticals by 2.7% during the 3rd quarter. Geode Capital Management LLC now owns 4,837,985 shares of the biotechnology company's stock worth $36,776,000 after purchasing an additional 127,708 shares in the last quarter. 85.88% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Wall Street Analysts Forecast Growth

A number of analysts have recently issued reports on the company. Evercore ISI increased their target price on BioCryst Pharmaceuticals from $10.00 to $12.00 and gave the company an "outperform" rating in a report on Monday, January 13th. HC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of BioCryst Pharmaceuticals in a research note on Tuesday, February 25th. JMP Securities reaffirmed a "market outperform" rating and set a $18.00 target price on shares of BioCryst Pharmaceuticals in a research note on Friday, January 31st. Wedbush began coverage on shares of BioCryst Pharmaceuticals in a research report on Tuesday, February 25th. They issued an "outperform" rating and a $15.00 price target for the company. Finally, Royal Bank of Canada restated an "outperform" rating and set a $11.00 price target (up from $10.00) on shares of BioCryst Pharmaceuticals in a report on Tuesday, February 25th. One research analyst has rated the stock with a hold rating and seven have issued a buy rating to the stock. Based on data from MarketBeat, BioCryst Pharmaceuticals currently has a consensus rating of "Moderate Buy" and a consensus target price of $15.57.

BioCryst Pharmaceuticals Trading Up 2.5 %

BCRX stock traded up $0.19 during trading on Wednesday, reaching $7.73. 2,868,150 shares of the stock were exchanged, compared to its average volume of 2,789,571. BioCryst Pharmaceuticals, Inc. has a twelve month low of $4.03 and a twelve month high of $9.50. The company has a market capitalization of $1.61 billion, a P/E ratio of -12.66 and a beta of 1.85. The stock has a 50 day simple moving average of $8.15 and a 200-day simple moving average of $7.86.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, February 24th. The biotechnology company reported ($0.13) earnings per share for the quarter, missing the consensus estimate of ($0.07) by ($0.06). The firm had revenue of $131.50 million during the quarter, compared to the consensus estimate of $126.64 million. The company's quarterly revenue was up 40.8% compared to the same quarter last year. During the same quarter in the previous year, the firm earned $0.28 earnings per share. Equities analysts predict that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current year.

About BioCryst Pharmaceuticals

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.